Sun sees brighter outlook, seeks new generic Doxil markets
This article was originally published in Scrip
Sun Pharmaceutical Industries reported sales and profit growth in excess of 50% for the second quarter ended 30 September as the performance of its businesses "exceeded plans", and the firm has revised upwards its full year revenue growth guidance to 25% from 18-20% previously.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.